Details of the Drug

General Information of Drug (ID: DMVY0BU)

Drug Name

Apaziquone

Synonyms

EOquin; 114560-48-4; Apaziquonum; NOR-701; EO 9 (pharmaceutical); EO-9; Apaziquone [USAN:INN]; NSC-382459; Apaziquonum [INN-Latin]; E 09; NSC 382459; UNII-H464ZO600O; E-85/053; E-09; EO9; NSC 382456; H464ZO600O; 5-(Azridin-1-yl)-3-(hydroxymethyl)-2-((1E)-3-hydroxyprop-1-enyl)-methyl-1H-indole-4,7-dione; (E)-5-(1-Azirinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-1H-indole-4,7-dione; E09; 1H-Indole-4,7-dione, 5-(1-aziridinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-, (E)-; Neoquin; Qapzola; Apaziquonum; EO 9; Eoquin (TN); Apaziquone (USAN/INN); E-85/050; 3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione)prop-beta-en-alpha-ol; 5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methylindole-4,7-dione; Apaziquone/EOquin

Indication

Disease Entry	ICD 11	Status	REF
Bladder cancer	2C94	Phase 3	[1]
Non-muscle invasive bladder cancer	2C94	Phase 3	[2]

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

288.3

Logarithm of the Partition Coefficient (xlogp)

-0.5

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

Chemical Identifiers

Formula: C15H16N2O4
IUPAC Name: 5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methylindole-4,7-dione
Canonical SMILES: CN1C(=C(C2=C1C(=O)C=C(C2=O)N3CC3)CO)/C=C/CO
InChI: InChI=1S/C15H16N2O4/c1-16-10(3-2-6-18)9(8-19)13-14(16)12(20)7-11(15(13)21)17-4-5-17/h2-3,7,18-19H,4-6,8H2,1H3/b3-2+
InChIKey: MXPOCMVWFLDDLZ-NSCUHMNNSA-N

Cross-matching ID

PubChem CID: 5813717
CAS Number: 114560-48-4
UNII: H464ZO600O
DrugBank ID: DB12593
TTD ID: D0FP0R

Drug-Molecule Activity Atlas (DMA)^NEW

Click to Jump to the Detailed DMA Information of This Drug

Drug ADMET Endpoint Profile (DAE)^NEW

Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human Deoxyribonucleic acid (hDNA)	TTUTN1I	NOUNIPROTAC	Modulator	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Solute carrier family 2, facilitated glucose transporter member 1 (SLC2A1)	OTA675TJ	GTR1_HUMAN	Drug Response	[4]

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000838)
2	ClinicalTrials.gov (NCT00598806) Phase 3 Trial of Single-Dose Intravesical EOquin as a Surgical Adjuvant for Noninvasive Bladder Cancer. U.S. National Institutes of Health.
3	EO9 (Apaziquone): from the clinic to the laboratory and back again
4	Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies. Cancer Chemother Pharmacol. 2008 Mar;61(3):377-93. doi: 10.1007/s00280-007-0480-1. Epub 2007 May 23.